Cargando…

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report

Chordoma is a rare primary bone tumor that exhibits insensitivity to radiotherapy and chemotherapy and has a poor prognosis. Currently, resection is the primary treatment for affected patients, but the subsequent rate of recurrence is high, and both overall survival (OS) and progression-free surviva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiaoli, Lin, Xiangwu, Chen, Ying, Kong, Wencui, Xu, Jinhe, Yu, Zongyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774333/ https://www.ncbi.nlm.nih.gov/pubmed/33392069 http://dx.doi.org/10.3389/fonc.2020.565945

Ejemplares similares

Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
por: Xu, Jinhe, et al.
Publicado: (2022)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis
por: Ndjana Lessomo, Fabrice Yves, et al.
Publicado: (2023)

Case Report: Immune Checkpoint Inhibitors as a Single Agent in the Treatment of Metastatic Cervical Cancer
por: Anipindi, Manasa, et al.
Publicado: (2022)

Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
por: Singh, Amisha, et al.
Publicado: (2022)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
por: Kamath, Suneel D., et al.
Publicado: (2018)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
por: Oishi, Hideo, et al.
Publicado: (2020)

Immune checkpoint inhibitor–induced diabetes mellitus with pembrolizumab
por: Zand Irani, Anis, et al.
Publicado: (2022)

Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
por: McCormick, Benjamin Joseph, et al.
Publicado: (2023)

Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review
por: Chen, Ying, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

CXCL1 Regulated by miR-302e Is Involved in Cell Viability and Motility of Colorectal Cancer via Inhibiting JAK-STAT Signaling Pathway
por: Chen, Biyin, et al.
Publicado: (2021)

Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab
por: Wang, Wei Cen, et al.
Publicado: (2023)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes
por: Wells, Leah, et al.
Publicado: (2022)

Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
por: Shinojima, Naoki, et al.
Publicado: (2023)

Metastatic chordoma
por: Suarez Conde, María Florencia, et al.
Publicado: (2019)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers
por: Wang, Yingnan, et al.
Publicado: (2023)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Wei, Yilun, et al.
Publicado: (2023)

Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid
por: Lorenz, Lisa, et al.
Publicado: (2019)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient
por: Kesari, Santosh, et al.
Publicado: (2023)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Analysis of prognostic factors affecting immune checkpoint inhibitor therapy in tumor patients exposed to antibiotics
por: Chen, Qian, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
por: Lavoie, Jean-Michel, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature
por: Braden, Jorja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v1pk97hk2gqokbvigf7dfne7ks